AstraZeneca reports results from Phase IV ATLANTIC study of Brilinta/Brilique

September 2, 2014 3:23 PM

1 0

AstraZeneca has announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients.

The data will be presented during the European Society of Cardiology congress1 taking place between 30 August and 3 September 2014 in Barcelona.

Read more

To category page